Skip To Main Content
Deze website is alleen bedoeld voor zorgverleners van België en Luxemburg.
Campus
  • Wetenschap
  • Artikelen
  • Opleiding
  • Andere onderwerpen
Campus
  • Wetenschap
  • Artikelen
  • Opleiding
  • Andere onderwerpen

Artikelen

Sort by

Filters

Resetten
  • Therapeutische gebieden

De kracht om de chaos van RSV te verminderen

Leer meer

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Leer meer

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Leer meer

Cardiovascular diseases (CVDs) are the leading cause of death globally

Leer meer

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Leer meer

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Leer meer

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Leer meer

When to suspect TTP?

TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.

Leer meer

What is TTP? A rare, life-threatening medical emergency

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

Leer meer

Signs and symptoms of aTTP

Know the signs and symptoms of acquired TTP (aTTP).

Leer meer

The Complex Burden of Autoimmune Type 1 Diabetes

Leer meer

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2

Leer meer